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ABSTRACT: 
 The present study objective was to develop novel 
colon specific drug delivery systems for aceclofenac using 
chitosan as a microbially degradable polymeric carrier and 
to coat the optimized batches with a pH dependent 
polymeric coating solution containing Eudragit L 100 and S 
100 (1:4). Tablets containing four proportions of chitosan 
were prepared. The tablets were evaluated for 
physicochemical properties, drug content, dissolution, 
water uptake & erosion characteristics, in vitro drug release 
studies. The amount of aceclofenac released from the 
chitosan tablets at different time intervals was estimated by 
UV spectrophotometric method at 275nm. Eudragit coated 
Chitosan tablets prevented release of the aceclofenac in the 
physiological environment of stomach and small intestine 
depending on the proportion of chitosan used in the 
formulation. The dissolution profile and in vitro release 
kinetics showed that chitosan tablets were promising for 
controlled delivery of the drug. The findings of the present 
study conclusively state that chitosan tablets are promising 
for colon targeting of aceclofenac to synchronize the 
chronobiological symptoms for effective treatment of 
rheumatoid arthritis.   
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INTRODUCTION 
Colon targeted drug delivery has the potential to 
deliver bioactive agents for the treatment of a variety of 
colonic diseases including inflammatory bowel disease 
(IBD) and rheumatoid arthritis  and  can be effectively 
treated by the local delivery of drugs to the large intestine. 
The treatment of colonic disease is particularly improved 
by their local delivery to the bowel. By this technique, 
absorption of the drug from the stomach and small intestine 
can be minimized until the drug reaches the large intestine. 
Various drug delivery systems have been designed that 
delivers the drugs quantitatively to the large bowel and 
subsequently to trigger the release of active drug.[1] Colon 
as a site offers distinct advantages on account of a near 
neutral pH, a much longer transit time, reduced digestive 
enzymatic activity and a much greater responsiveness to 
absorption enhancers. The colon is a site where both local 
and systemic drug delivery can take place. A local means 
of drug delivery could allow topical treatment of 
inflammatory bowel disease, irritable bowel syndrome. It is 
also preferred as an absorption site for oral administration 
of peptides drugs, because of the comparatively less hostile 
environment and low proteolytic enzyme activities in the 
colon. [2] ,[3] ,[4] 
Colon specific drug delivery has been the focus 
of importance now a days because, the large intestine is 
targeted not only for local diseases but also for systemic 
absorption. Various colon specific drug delivery systems 
are being developed, by taking advantage of the luminal pH 
in the ileum and microbial enzymes in the colon. It is 
extremely useful when a delay in drug absorption is 
required from a therapeutic point of view. eg. Angina 
pectoris, rheumatoid arthritis, and nocturnal asthma[5]. 
Four basic approaches have been exploited for colon 
specific drug delivery, namely prodrugs[6], pH dependent 
systems[7],[8], Time dependent systems[9] and Microbial 
degradable systems[10]. 
The microflora-activated systems formulated 
with non-starch polysaccharides are having potential 
because they remain as undegraded in the stomach and 
small intestine and degraded by the vast microflora of the 
colon where the release of the drug is 
required.Aceclofenac, a non steroidal anti-inflammatory 
drug used for the treatment of rheumatoid arthritis is 
selected as a model drug. The aim of the study was to 
design a novel colon specific drug delivery systems 
containing chitosan tablets coated with pH dependent 
polymers (Eudragit L 100 and S 100 in the ratio of 1:4). 
The goal in drug delivery research is to develop 
formulations to meet therapeutic needs related to particular 
pathological conditions. Variation of physiological and 
pathophysiological functions at a particular time of a day 
has brought a new approach to the development of drug 
delivery systems [11]. Rheumatoid arthritis (RA) is 
traditionally considered a chronic, inflammatory 
autoimmune disorder that causes the immune system to 
attack the joints. It is a disabling and painful inflammatory 
condition, which can lead to substantial loss of mobility 
due to pain and joint destruction [12]. Multiparticulate 
approaches tried for colonic delivery include formulations 
in the form of pellets, granules, microparticles and 
nanoparticles. The multiparticulate drug delivery systems 
are used in preference to single unit dosage forms for colon 
targeting. The multiparticulate systems enabled the drug to 
reach the colon quickly .The purpose of designing 
multiparticulate dosage form is to develop a reliable 
formulation that has all the advantages of a single unit 
formulations. [13] 
MATERIALS AND METHODS 
Materials 
Materials used included aceclofenac, which was 
kindly provided as a gift sample by Restek Pharma, 
Pondicherry. Chitosan was purchased from Indian Research 
Products, Chennai. Eudragit S 100 and Eudragit L 100 
were purchased from Loba chemicals, Mumbai. All other 
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Preparation of chitosan tablets
 
Step-I 
Matrix tablets, each containing 100 mg of 
aceclofenac and weighing 230 to 390 mg were prepared by 
wet granulation and direct compression techniques using 
chitosan as a polymer.  Formulations (F1–F4) were blended 
and granulated with different percentage of starch 
mucilage. The wet mass was passed through a mesh (1000 
μm) sieve and the granules were dried at 50°C for 2–3 h. 
The dried granules were sieved (650 μm), lubricated with 
magnesium stearate: talc   (1:2) mixture and compressed on 
a single-punch tablet machine, using 12 mm round slightly 
concave punches[14], [15]. The preparation of chitosan 




The optimized batch of chitosan tablets were 
coated with a combination of Eudragit L-100 and S-100 in 
a fluidized bed coating apparatus. In-process samples at 
various coating levels 5, 10 % w/w (% polymeric weight 
gain) were taken to check the morphology of coating to do 
dissolution studies in SGF fluid. Coating was continued 
until complete polymer weight gain was achieved. After the 
coating, the tablets were gently fluidized for  about 5 min 
after which they were air dried in an oven for 24 h at 40°C. 
A 10 % w/w increase in the coating level was selected as an 
optimum coating percentage level for all the tablets. Then 
the pH dependent polymeric coated tablets were tested for 




Differential scanning calorimetry 
In this technique the difference in energy inputs 
into a substance and reference material is measured as a 
function of temperature as the specimens are subjected to 
controlled temperature program.  
Fourier transforms Infrared spectroscopy 
 The Fourier transform infra-red analysis was 
conducted for the structural characterization. FTIR of pure 
drug, polymers, and their physical mixtures were recorded. 
Samples were taken in a KBr pellet using BOMEN MB 
SERIES FTIR instrument. 
Standard plot of aceclofenac in pH 7.0 phosphate buffer 
saline  
100 mg of aceclofenac (standard drug) was 
accurately weighed and dissolved using pH 7.0 phosphate 
buffer saline(PBS) solution in 100 ml standard flask and 5, 
10, 15, 20 and 25 µg/ml were prepared by suitably diluting 
the stock solutions with pH 7.0 PBS, each sample was then 
analysed spectrophotometrically at 275 nm using ELICO SL 
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Evaluation of granules[17] 
 Determination of bulk density and tapped density
 
An accurately weighed quantity of the powder 
(W), was carefully poured into the graduated cylinder and 
the volume (Vo) was measured. Then the graduated 
cylinder was closed with lid, set into the density 
determination apparatus. The density apparatus was set for 
100 tabs and after that, the volume (Vf) was measured and 
continued operation till the two consecutive readings were 
equal. The bulk density, and tapped density were calculated 
using the formulae 
                                                     Bulk density      = W / V0 
                                                      Tapped density = W / Vf 
                                                      Where, 
                                                     W= Weight of the powder 
                                                      V0 = Final volume 
 
Compressibility index (Cars indices) 
Compressibility index was calculated by using the formula 
                             (V0 – Vf) 
Ci  =        ------------------------ x 100 
                                  V0 
                
 
   
 
Ci < 15 % shows good flow property 
Ci > 25 % shows poor flow property 
Ci >50 % shows great potential problems. 




Hausner’s ratio was measured by the ratio of 
tapped density to bulk density. 
Hausner’s ratio = Tapped density/ Bulk density 
 Evaluation of Tablets[18-20] 
Tablet hardness was measured with a monsanto 
tester. The hardness  of 10 tablets was measured, and the 
mean hardness was calculated and reported. The tablet 
friability was determined on a Coel HX-4 friabilator. The 
weight of 20 tablets was measured on an analytical balance 
(Mettler H15) and then loaded into the friabilator. After 
100 revolutions, the tablets were removed, dedusted, and 
reweighed. The difference of the weight was calculated as a 
percent loss. 
Diameter and thickness were measured using Paquimetre 
Mitutoyo for 10 tablets. To study weight variation, 20 
tablets were weighed individually using an electronic 
balance (Mettler H15), and the test was performed 
according to the official method. 
The drug content was determined by crushing and 
powdering five  tablets. The amount of powder equivalent 
to the mean of these five tablets was weighed in 100 mL of 
water and the volume adjusted to 200 mL. After 20 minutes 
of centrifugation, aliquots of 1 mL were taken from this 
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solution and diluted to 100 mL with water. Absorbance of 
resulting solutions was measured in a spectrophotometer at 
257 nm. Simultaneously, a 10 μg/mL of aceclofenac 
standard solution prepared in the same medium was 
recorded. Content of aceclofenac was calculated.   
 
In Vitro Drug Release Studies in Simulated Fluids[21] 
Tablets were evaluated for the in vitro drug 
release in simulated GI fluids (SGF). The drug dissolution 
test of tablets was performed by the paddle method 
specified in USP XXIII. Tablets were dissolved over the 
surface of 500 mL of dissolution medium (SGF). The 
content was rotated at 100 rpm at 37°C ± 0.5°C. Perfect 
sink conditions prevailed during the drug dissolution study 
period. The simulation of GI transit condition was achieved 
by altering the pH of dissolution medium at different time 
intervals. The pH of the dissolution medium was kept 1.2 
for 2 hours then, the pH of the dissolution medium was 
adjusted to 7.4 and maintained up to 24 hours. The samples 
were withdrawn from the dissolution medium at various 
time intervals using a pipette fitted with a microfilter. The 
receptor volume was maintained constant by replacing 
equivalent amount of SGF and SIF. The concentration of 
aceclofenac in the samples was calculated based on average 
calibration curves (n = 6). All dissolution studies were 
performed in triplicate. 
In Vitro Drug Release Study in the Presence of Rat 
Cecal Content[21] 
Rat cecal content was prepared by the method 
reported by Van den Mooter et al. Four albino rats of 
uniform body weight (150-200 g) with no prior drug 
treatment were used for all the present in vivo studies. They 
were weighed, maintained on normal diet, and administered 
1 mL of 2% dispersion of chitosan in water, and this 
treatment was continued for 7 days for polymer induction 
to animals. Thirty minutes before starting the study, each 
rat was humanely killed and the abdomen was opened. The 
cecal were traced, legated at both ends, dissected, and 
immediately transferred into phosphate buffered saline 
(PBS) pH 6.8, which was previously bubbled with CO2. 
The cecal bag was opened, the contents were weighed, 
homogenized and then suspended in PBS (pH 7.4) to give 
the desired concentration (2%) of cecal content, which was 
used as simulated colonic fluid. The suspension was 
filtered through cotton wool and ultrasonicated for 10 
minutes in an ice bath at 40% voltage frequency using a 
probe sonicator (Soniweld, Imeco Ultrasonics, Mumbai, 
India) at 4°C to disrupt the bacterial cells. After sonication, 
the mixture was centrifuged (Remi) at 2000 rpm for 20 
minutes. 
Tablets were placed in 200 mL of dissolution 
media (PBS, pH 7.4) containing 2% w/v rat cecal content. 
The experiment was performed with continuous 
CO2 supply into the dissolution medium. At different time 
intervals, the samples were withdrawn and replaced with 
fresh PBS. The experiment was continued up to 24 hours. 
The withdrawn samples were pipetted into a series of 10 
mL volumetric flasks, and volumes were made up to the 
mark with PBS and centrifuged. The supernatant was 
filtered through 0.45-µm membrane filter and the filtrate 
analyzed for aceclofenac content at 275 nm using UV 
spectrophotometer method. All the experiments were 
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Quantification of the Water Uptake and Erosion 
Determination[22]
 
For conducting water uptake studies, the 
dissolution jars were marked with the time points of 0.5, 1, 
2, up to 9 hours. One tablet was placed in each dissolution 
jar containing 900 ml of phosphate buffer pH 7.4 buffers at 
37°C ± 0.5°C, and the apparatus was run at 100 rpm using 
paddle. The tablets were taken out after completion of the 
respective stipulated time span as mentioned above and 
weighed, after the excess of water at the surface had been 
removed with filter paper. The wetted samples were then 
dried in an oven at 40°C up to constant weight. The 
increase of the weight on the tablet reflects the weight of 
the liquid uptake. It was estimated according to Equation1 
 




Where Q is the percentage of the liquid uptake, 
and Ww and Wi are the masses of the hydrated samples 
before drying and the initial starting dry weight, 
respectively. 
The degree of erosion (expressed as percentage erosion of 
the polymer content, E) was determined using Equation 2 
E = 100 ( W i − W f ) W i (2) 






The entire process was repeated to get 3 values for each 
time point, and the average was calculated. 
 Stability studies 
The selected formulation of tablets were stored in 
amber-colored glass bottles at 45ºC+75% RH for a period 
of 3 months and observed for any change in colour, odour, 
and percentage drug content and entrapment efficiency. 
 
In vitro release kinetics[23] 
The in vitro drug release data were fitted to 
various release kinetic models. viz. first order, zero order 
model, Higuchi and Korsemeyer - Peppas equation. The 
goodness of fit was found out from the above mathematic 
models.  
RESULTS AND DISCUSION 
DSC studies 
DSC provides information about the physical 
properties of the sample as crystalline or amorphous nature 
and demonstrates a possible interaction between drug and 
polymers in formulations. According to the thermo grams, 
aceclofenac presented a sharp endothermic peak at 158.3ºC 
corresponding to the melting point of the drug in the 
crystalline form. While the thermogram of physical mixture 
of aceclofenac and chitosan was 158.7ºC.  
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However a broad endothermic peak observed for 
chitosan at 92.0ºC. Thus the thermograms of physical 
mixture showed that drug was in its crystalline form and 
also there is no interaction between the aceclofenac and the 
polymer .The DSC graphs are given in fig. 1-3. 
IR studies 
The FTIR of aceclofenac showed intense bands  
at 1771.47 cm-1, 1716.89 cm-1 , 1589.53 cm-1 and 1055.9 
cm-1 corresponding to the functional groups C=O, COOH, 
NH and OH bending respectively. The peaks observed in 
FTIR of physical mixture of aceclofenac and chitosan were 
1771.69 cm-1, 1716.89 cm-1, 1589.72 cm-1, 1056.13 cm-1 
respectively for the above mentioned functional group. 
From the above interpretation it was understood that there 
was no major shifting in the frequencies of aceclofenac 
which indicated that there is no chemical interaction 
between aceclofenac and polymer which were used in the 
formulations. The FTIR spectra were given in fig. 4-6 
respectively. 
Micromeritic properties 
When micromeritic properties of all the 
formulations were compared and it was found that ACHT1 
batch was optimal due to Hausner’s ratio (1.15), carr’s 
index (14.96) and angle of repose (17°06’) were within the 
specified limit and were good. The results for micromeritic 
properties of all the formulations were given in table 2 
Physical properties 
The hardness varied from 4.12 ± 1.06 to 6.21 ± 
0.82 kg/cm2 for ACHT1 to ACHT4 tablets made with 22 % 
w/w to 51.2 % w/w of guar gum to tablet weight 
respectively. The other test such as weight variation, 
thickness and friability and percentage drug content were 
within the pharmacopoeial limits. The results for physical 
properties of all the formulations were given in table 3. 
Percentage swelling  
The swelling was 9.9% for ACHT1 and it 
increased to 24.8% for ACHT4 in 30 min with the increase 
in the polymer concentrations as due to more of the 
polymer caused more water uptake and thus swelling 
increased. The swelling increased for first 3 hours upto 
33.1% for ACHT1 and thereafter shown a declining trend, 
while in case of other formulation it increased upto 5 hours 
due to increased polymer concentrations and after that the 
swelling decreased gradually. The results for percentage 
swelling of ACHT were shown in fig. 7. 
Percentage erosion 
The percentage erosion decreased from 16.4 % 
(ACHT1) to 1.2 % (ACHT4) at 30
th min of the study. At the 
end of 8th hour the values were 98.6 and 26.0% for ACHT1 
and ACHT4 respectively. As time of study increased, the 
erosion increased. The erosion in SCF revealed that the 
colonic enzymes present in the caecal contents in the buffer 
solution helped in degrading the polysaccharide and 
thereby erosion started. It took almost 8 to 12 hour for the 
complete degradation of the polymer (chitosan) in the 
colonic fluid. The ACHT1 released maximum amount of 
drug at the end of 8th hour in SCF, thus it was considered to 
be the optimized batch, because it released about 101.16 % 
in colonic fluid at the 8th hour of the study selected for the 
pH dependent polymeric coating. The results for percentage 
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In vitro drug release studies in SGF, SIF and SCF. 
In SGF (pH 1.2 buffer) 
In the simulated gastric fluid, the ACHT1 batch 
started release at 15 min and a maximum release of 21.12 ± 
1.2 % of the drug found at the end of 120 min of the study. 
This highest percentage of drug release is due to the 
solubility of chitosan in acid which is its inherent property. 
The batch ACHT2 released about 16.28 ± 0.82 % and 
ACHT3 and ACHT4 released about 13.62 ± 0.12 and 8.12 ± 
0.82 % of drug for the same time period respectively. The 
decrease in the percentage was due to more complex 
structure which is in turn due to increased concentration of 
chitosan from ACHT1 to ACHT4. It reveals that the time 
taken for the solubility of chitosan increases as the chitosan 
concentration increased.  
Percentage drug release in SIF (pH 7.4 buffer) 
There was no release for the first two 
formulations ACHT1, ACHT2 at 30 min while there found a 
minimal release for the next two formulations namely 
ACHT3, ACHT4. However the release was 1.10 ± 1.2% for 
ACHT1 and it increased gradually with the increase in 
polymer concentration and it was 6.92 ± 0.82% for ACHT4 
at 1h. The release rate increased with the prolongation of 
time and it was 22.01±0.54 %  for ACHT1 at the end of 6
th 
hour and 36.21±0.23 % for ACHT4 for the same period of 
time.  The results for in vitro drug release in SIF were 
shown in fig.9.          
Cumulative percentage drug release in SCF (pH 7.4 
buffer with enzyme) 
Due to the abundance of colonic enzymes in the 
colonic fluid, the release started immediately so that 
percent release was 12 ± 0.26% (ACHT1) at 30 min and it 
decreased as the polymer concentration increased as release 
was 6.25 ± 0.17 % for ACHT3 and no release for ACHT4. 
The drug release increased proportionately with time and 
reached to 101.16 ± 1.0 % at the end of 8th hour for the 
ACHT1 and while the release rate decreased according to 
the increase in polymer concentration to 33.38 ± 0.26 % for 
ACHT4 for the same time period. The same results were 
observed by orient et al.28 The results for in vitro drug 
release in SCF were shown in fig.10. Based on the above in 
vitro results the batch ACHT1 was selected as the optimized 
batch as it released maximum amount of drug at 8th hour 
and also possessed good micromeritic and physicochemical 
properties.  
Step II 
Thus the batch ACHT1 was given pH dependent 
polymeric coating as explained under the general 
methodology until to get a weight increase of 10 % w/w. 
There was absolutely no release in SGF, where as in SIF, it 
released upto 9.2 ± 0.62% which was less than the uncoated 
tablets. This was due to the pH dependent solubility of the 
coating layer. In SCF, the percentage drug release was 
102.24 ± 1.2 which was comparable with the uncoated 
tablets. Though the polymeric coating dissolved at SIF 
itself the internal fluid causes swelling. But when it was 
brought in contact with the SCF which contains microbial 
enzymes, it swelled upto 3 hours and then enzymes 
penetrated into the gel layer of the tablet and caused the 
erosion of the gelled layer which made the high percentage 
drug release. So, it was evident from the results that the 
ACHT1 batch is a promising formula to target the colon. 
The results for Cumulative drug release in SIF and SCF of 
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In vitro release kinetics 
When the data were plotted according to the first 
order equation, all the formulation showed a fair linearity, 
with R2 value between (0.8001- 0.8026), when the same 
data was plotted according to the zero order equation, it 
shown a good linearity with R2 value between (0.9623 - 
0.9883).  In our experiment, the in vitro release profiles of 
aceclofenac could be best expressed by Higuchi’s equation, 
as the plots showed good linearity ,thus confirmed that the 
mode of release was diffusion while to further confirm the 
diffusion mechanism, the data were fit into Korsmeyer et al 
equation, which showed high linearity with a comparatively 
high slope  value. This n-value, however appear to indicate 
a coupling of diffusion and erosion mechanism – so called 
anomalous diffusion. Presence of swelling polymers within 
the matrix structure might be responsible for the drug 
release controlled by more than one process. It showed a 
non fickian mode of release.  
Stability studies 
The stability studies revealed that ACHT1 
formulae did not show any changes in its appearance and 
drug content after 3 months at an accelerated temperature 
and humidity condition.  
 
            Table: 1 Preparation of the chitosan tablets 
Ingredients (mg) 
Quantity (mg) present in each tablet 
ACHT1 ACHT2 ACHT3 ACHT4 
Aceclofenac 100 100 100 100 
Chitosan 50 100 150 200 
Microcrystalline cellulose 25 25 25 25 
Mucilage of starch 7.5 % 18 20 20 21 
Magnesium stearate 3% 7 8 10 11 
Talc 2% 5 6 7 8 
Starch powder 25 25 25 25 
Total 230 284 337 390 












Table:2 Micromeritic properties of aceclofenac and chitosan granules  
Test ACHT1 ACHT2 ACHT3 ACHT4 
Bulk density 0.588 0.611 0.638 0.698 
Tapped density 0.676 0.714 0.759 0.844 
Carr’s index 14.96 16.85 18.96 20.91 
Hausner's ratio 1.15 1.17 1.19 1.21 
Angle of repose 17°06’ 17°01’ 18°26’ 19°42’ 
 
                                    Table:3 Physical properties of aceclofenac and chitosan tablets  
Test ACHT1 ACHT2 ACHT3 ACHT4 
Weight (mg) 232 ± 1.02 284 ± 0.87 337 ± 0.67 392 ± 0.65 
Drug 100.40 ± 0.98 99.27 ± 0.78 99.97 ± 0.78 99.7 ± 0.8 
Hardness kg/cm2 4.12 ± 1.06 4.8 ± 0.45 5.6 ± 0.34 6.21 ± 0.4 
Thickness (mm) 3.0 ± 0.6 3.3 ± 0.76 4.24 ± 0.56 4.4 ± 1.0 
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    Fig: 4 IR of Aceclofenac 
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    Fig: 6 IR of Aceclofenac and Chitosan 
 
 











                         Fig:8 Percentage erosion of aceclofenac and Chitosan tablets in SCF 
 
 











                        Fig: 10 Cumulative percentage drug release of ACHT  in SCF 
 
 











The objective of the present study was to develop 
a controlled release colon targeted drug delivery system of 
aceclofenac, the non steroidal anti-inflammatory drug to 
approximate the chronobiology of rheumatoid arthritis. The 
system as a potential value when a delay in absorbtion is 
desired from a therapeutic point of view in the treatment of 
disease such as rheumatoid arthritis which have peak 
symptoms in early morning. Research in this so called 
chronopharmacological field has assumed significance in 
developing drug delivery systems that demonstrate the 
importance of biological rhythms in drug therapy. 
Of the several approaches of colon specific 
delivery of drugs, a combination of coating with pH 
sensitive polymers and embedding in biodegradable 
matrices has been followed for preparation of formulations. 
The combination of these two polymers in a various ratios 
makes it possible to manipulate drug release within pH 
range of 6.0 to 7.0. The matrices of polysaccharides are 
assumed to remain intact in the physiological environment 
of stomach and small intestine. But once they reach the 
colon they are acted upon the bacterial polysaccharidases 
and results in the degradation of the matrices.  
Chitosan have been reported to possess ideal 
qualities for sustained release of the drug to the targeted 
site (colon). Colon-specific delivery of the investigational 
drug (aceclofenac) was aimed through tablets in order to 
ascertain the efficacy of these formulations for delivery of 
drug to the colon. It has been reported that polymer 
concentration is found to influence the release characters of 
the drug from the dosage form.  Chitosan in varying 
concentrations (22, 35, 45 and 51% w/w total tablet weight) 
did not influence the physical characteristics of the tablets, 
however the swelling index and the percentage erosion 
appears to be dependent on polymeric concentration. 
Taking into account the dissolution profile of chitosan-
aceclofenac tablets, the ACHT1 was an optimized 
formulation as its dissolution profile was akin to the 
expected requirements of the study. The eudragit coating of 
the optimized formulation E-ACHT1 has reduced the drug 
release to the extent of about 9.2 ± 0.02 %, however 
maintain the same dissolution profile in SCF thus 
suggesting that chitosan seems to be superior to other 
polymer in influencing the drug release 
characteristics.From the overall results on the behavior of 
chitosan-aceclofenac tablets, it appears promising, since the 
drug release could be a result of the combination of fine 
dependent hydration of chitosan and enzymatic degradation 
by colonic bacteria.  
CONCLUSION 
The present study focussed on viability of tablets 
of aceclofenac with polymer chitosan for controlled and 
colon specific delivery in chronotherapy of rheumatoid 
arthritis. The in vitro studies suggest that a chitosan tablet 
of aceclofenac is promising for therapy of rheumatoid 
arthritis. A further detailed study in human subjects will 
through more light on their efficacy and compliance. 
ACKNOWLEDGEMENT 
I would like to extend my first words of thanks to 
Dr. Ravichandiran., Principal, School of Pharmaceutical 
Sciences, Vels university and Mr. Ishari Ganesh, Director, 





JPRHC                January 2010                   Volume 2                 Issue 1              46-65  
 
REFERENCES: 
1. Rang HP, Dale MM. Pharmacology. 1st ed, 1988, 
609; UK.  
2. Vyas. S. P and Roop. K. Khar. Controlled Drug 
Delivery Concepts and Advances; Vallab 
Prakashan, New delhi;  218-256.  
3. Lamprecht alf, Yamamoto Hiromitsu, Takeuchi 
Hirofumi, Kawashima Yoshiyaki. Design of pH-
sensitive tablets for the colonic delivery of the 
immunosuppressive drug tacrolimus.  Eur. J. 
pharm and biopharm, 58, 2004; 37-43. 
4. Jack Aurora and Naresh Talwar. Colonic drug 
delivery challenges and opportunity- An 
overview. Eur. Gastro. Rev (1) 2006; 165. 
5. Rubinstein A. Approaches and opportunities in 
colon – specific drug delivery. Crit Rev Ther 
Drug Carrier Syst, 12b, 1995; 101 – 149. 
6. Mc Leod. A.D, Friend,D.R, Tozer. T.N. 
Synthesis and chemical stability of 
glucocorticoid- dextran esters: potential prodrugs 
for colon-specific delivery. Int. J. Pharm, 92, 
1993; 105-114. 
7. Ashford. M, Fell J.T, Attwood. D, Sharma.H, 
Woodhead.P.J. An invivo investigation into the 
suitability of pH dependent polymers for colonic 
targeting. Int. J. Pharm, 95, 1993; 193-199.  
8. Khan. M. Z, Prebeg. Z, Kurjaković. N.  A pH-
dependent colon targeted oral drug delivery 
system using methacrylic acid copolymers. I. 
Manipulation Of drug release using Eudragit L-
100-55 and Eudragit S-100 combinations. J 
Control Release,29, 58(2), 1999; 215-222. 
9. Fukui.E, Miyamura. N, Uemura. K, Kobayashi. 
M. Preparation of enteric coated timed release 
press coated tablets and evaluation of their 
function by In vitro and in vivo tests for colon 
targeting. Int J Pharm, 204 (1-2), 2000: 7-15.  
10. Ashford.M, Fell. J.T. Targeting drugs to the 
colon: delivery systems for oral administration. J   
Drug Target,2(3), 1994; 241-257. 
11. Brahma N. Singh. Modified Release solid 
formulations for colonic delivery. Recent patents 
on drug delivery and formulations. (l), 2007; 53-
63. 
12. Patrick D. Wall and Ronald Melzack.. Text book 
of pain, 13th edn, Churchill livingstone, 2006, 
653-667, UK. 
13. Sindhu Abraham and Srinath. M. S. Development 
of modified pulsincap drug delivery system of 
metronidazole for drug targeting. Ind J Pharm 
Sci, 2007, 24-27. 
14. Munira Momin, pundarikakshudu. K. In vitro 
studies on guar gum based formulations for the 
colon targeted delivery of sennosides. J Pharm 
Pharmaceut, 7(3), 2004; 325-331,. 
15. Liu. L, Fishman. M.L, Kost. J, Hick. K. B.  
Pectin based systems for colon – specific drug 
delivery via oral route. Biomaterials, 246, 2003; 
3333 – 43. 
16. Gang Cheng, Feng An, Mei-Juan Zou, Jin Sun, 
Xiu-Hua Hao, Yun-Xia He. Time- and pH- 
dependent colon-specific drug delivery for orally 
administered diclofenac sodium and 5- 
aminosalicylic acid. World J Gastroenterol, 10 
(12), 2004; 1769-1774. 
17. Indian Pharmacoepoia.; vol II, Controller of 
publications, Ministry of Health ; 1996,   789- 
801. 
18. Chourasia. M. K, Jain. S. K. Pharmaceutical 
approaches to colon targeted drug delivery 
JPRHC 
Research Article 
JPRHC                January 2010                   Volume 2                 Issue 1              46-65  
 
systems,  J Pharm  pharamaceut Science, 6(1), 
2003; 33 – 36. 
19. Encyclopedia of pharmaceutical technology; 3rd 
edition; James swarbrick; Vol.6;       2614-2629. 
20. Evelyn Ojoe, Edna Mitie Miyauchi, Tais Cobo 
Viviani, Vladi Olga Consiglieri. Formulation and 
in vitro evaluation of theophylline-Eudragit 
sustained-release tablets; Brazilian Journal of 
Pharmaceutical Sciences,  41(3),2005. 
21. Paharia .A, Yadav. A. K, Rai. G, Jain. S.K, 
Pancholi. S. S, Agrawal. G.P. Eudragit-coated 
Pectin Microspheres of 5-Fluorouracil for Colon 
Targeting. AAPS PharmSciTech. 8(1), ( 2007. 
22. Avachat A, Kotwal V. Design and Evaluation of 
matrix-based controlled release tablets of 
diclofenac sodium and chondroitin sulfate.  
AAPS pharm SciTec, 8(4), 2007, 88;  E1-E8. 
23. Hadi Mehrgan and Seyed Alireza Mortazavi. The 
Release Behavior and Kinetic Evaluation of 
Diltiazem HCl from Various Hydrophilic and 
Plastic Based Matrices. Iran J Pharm Research, 3, 
2005, 137-146. 
AUTHOR AFFILIATIONS: 
  School of pharmaceutical sciences 
  Vels university, chennai- 117 












ADDRESS FOR COMMUNICATION: 
R. Thiruganesh 
Assistant Professor, Dept. of Pharmaceutics 
School of Pharmaceutical Sciences 
Vels University, Chennai- 117 
India  
Cell: +91-9618144271 
E-Mail: gracewell.nic@gmail.com 
 
 
 
 
 
